Abiomed Impella RT-DAQ - Observational Study

Launched by ABIOMED INC. · Mar 12, 2024

Keywords

ClinConnect Summary

The Abiomed Impella RT-DAQ trial is an observational study focused on understanding how patients with cardiogenic shock— a serious condition where the heart can't pump enough blood— respond to Impella support. The study aims to gather real-time data on heart function for patients who are currently receiving or are planned to receive this type of heart support in intensive care. To be eligible, participants should be between 65 and 74 years old, and they need to have a way to measure their heart's output, typically using a special catheter that helps doctors monitor heart performance closely.

If you or a family member are considering joining this study, you should know that it is currently open for recruitment. Participants will be closely monitored while receiving care with the Impella device, which helps support heart function. However, this trial is not suitable for anyone under 18, pregnant individuals, or those expected to need support for less than 24 hours. This study could provide valuable insights into the best ways to treat patients in critical condition and improve their chances of recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Ongoing or planned intensive care management with Impella support
• • 2. Presence or planned placement of a cardiac output measurement
• • 1. Preferentially pulmonary catheter (including cardiac output (CO) preferred as continuous measurement)
• • 2. Other means of discontinuous CO measurement incl. echocardiography, other thermodilution methods
• Exclusion Criteria:
• • 1. Age \< 18 years
• • 2. Pregnancy
• • 3. Anticipated support duration \<24 h